Eli Lilly and Co. and will acquire Alnara Pharmaceuticals, a privately held biotech company developing protein therapeutics for the treatment of metabolic diseases. Alnara’s lead product is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), currently under review by the FDA for the treatment of exocrine pancreatic insufficiency (EPI). Financial terms were not disclosed. “The acquisition of Alnara provides Lilly with a promising entry into enzyme replacement ...